Promena hemijskog sastava korena kao rani indikator rizomanije šećerne repe

The aim of investigation was monitoring of change of chemical composition of sugar beet root juice in dependence of presence, that is the absence of rhizomania, as well as the intensity of the occurrence this disease in tolerant and susceptible sugar beet hybrids because of establishing of early indicators of this disease occurrence in fields of Agriculture Corporation 'Belgrade'. Considering to the specificity of production area of PKB and to the different claims about some changes of root components in plants with rhizomania, and what is connected as well as with the soil and climatic conditions in which the investigations were done, it is necessary a permanent monitoring of chemical composition of root juice because of the confirmation and monitoring of the spread of this severe sugar beet disease. On the basis of chemical analysis of sugar beet root we can conclude that increased content of sodium followed by the decrease of sugar content in sugar beet root can serve as an early indicator of occurrence of this disease. Only sodium content increase, that is decrease of sugar content in sugar beet root are not reliable indicators the occurrence or the intensity of rhizomania onset regarding the great influence of sugar beet genotype and agro-ecologic conditions in which beet is growing. .Cilj istraživanja bio je praćenje izmena hemijskog sastava soka korena šećerne repe u zavisnosti od prisustva odnosno odsustva rizomanije, kao i intenziteta pojave ove bolesti kod tolerantnih i osetljivih hibrida šećerne repe radi utvrđivanja ranih pokazatelja pojave ove bolesti na poljima Poljoprivredne korporacije 'Beograd'. S obzirom na specifičnost proizvodnog područja PKB i ne podudaranja tvrdnji o pojedinim promenama sastojaka korena kod obolelih biljaka od rizomanije, a što je povezano kako sa ispitivanim genotipovima šećerne repe i patogena, tako i sa zemljišnim i klimatskim uslovima u kojima su ispitivanja izvršena, neophodno je stalno praćenje hemijskog sastava soka korena radi potvrđivanja i praćenja širenja ove opake bolesti šećerne repe. Na osnovu hemijskih analiza soka korena šećerne repe možemo zaključiti da povećan sadržaj natrijuma praćen smanjenjem sadržaja šećera u korenu šećerne repe može poslužiti kao rani indikator pojave ove bolesti. Samo povećanje sadržaja natrijuma, odnosno smanjenje sadržaja šećera u korenu šećerne repe nisu sigurni pokazatelji pojave ili intenziteta napada rizomanije s obzirom na veliki uticaj genotipa šećerne repe i agroekoloških prilika u kojima repa raste

Prsten

Književni deo "Jevrejskog almanaha" u kome je objavljena priča Vesne Demajo "Prsten", odnosi se na literarne radove sa jevrejskom tematikom iz oblasti istorije, književnosti, umetnosti, memoarske građe i Holokausta. Neki od radova iz ove rubrike objavljuju se po prvi put, neki su objavljeni i na drugim mestima a neki su delovi većih celina (zbirki, romana, memoarske građe, dnevnika i sl.).The literary section of the "Jewish Almanac" where is published story "Prsten" by Vesna Demajo, refers to literary works on Jewish topics in the fields of history, literature, art, memoirs, and Holocaust. Some of the works in this section are published for the first time, some have been published elsewhere and, some are parts of larger entities (collections, novels, memoirs, diaries, letters, etc.)

SERBIA AND MONTENEGRO

Elevated plasma levels of TGFbeta1 in patients with locally advanced breast cancer related to other clinical stage

Case with triple-negative breast cancer shows overexpression of both cFOS and TGF-beta 1 in node-positive tissue

We present herein a case report style article on a rare advanced triple-negative breast cancer (TNBC) patient with 6-month disease-free interval, and 10-month overall survival. Our results demonstrate that the poor clinical outcome of this patient was associated with pronounced, more than fivefold higher, overexpression of both cFOS and TGF-beta 1 proteins in its metastatic nodal tissue extracts, when compared with the values of the two non-TNBC controls (with zero disease-free interval and overall survival). This original observation suggests, for the first time, that both the cFOS and TGF-beta 1 may be considered as a pair of biomarkers for an early assessment of poor prognosis for TNBC patients. The possible clinical implication of this observation is discussed

Detection of transforming growth factor-beta 1 in human plasma - A pilot study on breast cancer patients

There has been much controversy concerning the detection of plasma TGF-beta (1) levels in breast cancer patients. The present study provides preliminary evidence on underestimated plasma TGF-beta (1) levels due to ex vivo proteolysis and previous therapeutic treatment of breast cancer patients, as detected by a commercial ELISA immunoassay. Our results revealed that the addition of protease inhibitors: phenylmethylsulfonyl fluoride and aprotinin, to the plasma preparation of healthy volunteers, has increased TGF-beta (1) median Value from 3.1 ng/mL to 33.9 ng/mL. Relative to that, in protease-inhibited plasma of locally advanced/metastatic breast cancer patients, significantly elevated TGF-beta (1) was observed (median value: 65.5 ng/mL), which included untreated and previously treated patients with median values of: 74.2 ng/mL and 58.1 ng/mL, respectively. These findings indicate to the potential usefulness of this plasma marker in breast cancer prognosis, thus deserving future clinical attention

Plasma TGF-beta 1-related survival of postmenopausal metastatic breast cancer patients

A pilot study was conducted to assess whether plasma levels of transforming growth factor-beta 1 (TGF-beta 1) might facilitate biological subgrouping of postmenopausal metastatic breast cancer patients, and, accordingly, its applicability in clinical oncology. This study included 29 postmenopausal metastatic breast cancer patients. Plasma TGF-beta 1 levels were detected by enzyme-linked immunosorbent assay (ELISA). Estrogen and progesterone receptors were assayed by radioligand binding, in accordance with the recommendation of the EORTC. Concentrations of 17-beta estradiol were determined by using ELISA-microwell method (DIALAB). Overall survival was followed for 24 months for each individual patient. Stratification of the patients by ER/PR status showed that 14 patients with estrogen receptor-negative, progesterone receptor-negative carcinomas displayed a statistically significant increase in plasma TGF-beta 1 levels when compared to plasma TGF-beta 1 levels of 6 patients with ER-positive, PR-positive carcinomas (P=0.04). In this study, 7 out of 14 patients with negative receptors status had no plasma TGF-beta 1 values overlapping with patients having positive receptors status. The TGF-beta 1 cut-off value was defined as the highest plasma TGF-beta 1 level of ER-positive, PR-positive patients: 3.28 ng/ml. This plasma TGF-beta 1 cut-off value defined low-risk subgroup of 19 patients (! 3.28 ng/ml) and high-risk subgroup of 10 patients ( GT 3.28 ng/ml) (P=0.047). Plasma TGF-beta 1-related survival was independent of the classical prognostic factors of metastatic breast cancer. Accordingly, a clinical significance of elevated plasma TGF-beta 1 levels may be suggested

TGF-beta1 in breast cancer-estrogen regulation

TGF-beta1 is a pluripotent cytokine with diverse effects in the normal development of mammary glands, and in the development of malignant tumors of the breast. The aim of the study was to determine the levels of TGF-beta1 in the group of advanced breast cancer, in which increased TGF-beta1 levels were most likely to be expected. TGF-beta1 levels were also compared with estradiol levels. Our results suggested that TGF-beta1 synthesis may be regulated by estrogen or anti-estrogen through ER. Finding of increased TGF-beta1 levels, due to its possible role in predicting invasive phenotype in later phases of tumor progression, may indicate the tendency of tumor tissue towards autonomy

Quantification of Transforming Growth Factor Beta 1 Levels in Metastatic Axillary Lymph Node Tissue Extracts from Breast Cancer Patients A New Specimen Source

OBJECTIVE: To use cytoplasmic tissue extract as a new specimen source to quantify transforming growth factor beta 1 (TGF beta 1) protein in metastatic axillary lymph node tissue (ALNT) of breast cancer (BC) patients and to confirm the feasibility of this approach in a prospective pilot study on a subgroup of patients with invasive BC. STUDY DESIGN: The 6 selected malignant and autologous nonmalignant pairs of ALNT were fractionated, under special preanalytical, nonaggressive/nondenaturing conditions, to obtain respective cytoplasmic extracts for TGF beta 1 detection by the Quantikine (R and D Systems Inc., Minneapolis, Minnesota, U.S.A.) enzyme-linked immunosorbent assay kit. RESULTS: The data indicated a highly significant (r=0.973054) positive linear correlation between the TGF beta 1 concentration and total protein concentration in cytoplasmic extract of metastatic ALNT. The subsequent patients pilot study, performed strictly before any clinicopathologic factors were accessible, revealed significantly (p LT 0.01) elevated TGF beta 1 in malignant ALNT (median value: 1.05 ng/mg protein, range: 0.67-3.6 ng/mg protein, n=6) vs. autologous nonmalignant ALNT controls (median value: 0.48 ng/mg protein, range: 0.29-0.90 ng/mg protein, n=6). This elevation was correlated with the number of metastatic axillary lymph nodes with respect to the total and was consistent with an increase in size of tumor deposits in axillary lymph nodes. CONCLUSION: Our data provide for the first time suggestive evidence that the TGF beta 1 level in cytoplasmic extracts of metastatic ALNTs may be a promising bio-marker of invasiveness for BC patients. Confirmatory, large-scale studies are needed to evaluate possible implications of this putative biomarker in BC diagnosis and treatment. (Anal Quant Cytol Histol 2009;31:288-295

Elevated plasma TGF-beta(1) levels correlate with decreased survival of metastatic breast cancer patients

Background: The role of circulating TGF-beta(1) in prognosis of breast cancer (BC) was investigated with an intention to define TGF-beta(1)-dependent high risk and low risk subsets of patients. Methods: Fifty three BC patients of all clinical stages and 37 healthy donors (HD) were analyzed for plasma TGF-beta(1) by the T beta RII receptor-based Quantikine TGF-beta(1) ELISA kit. Results: The plasma TGF-beta(1) level of Stage I/II disease (median: 0.94 ng/ml; n=10)) remained close to HD (median: 1.30 ng/ml; n = 37; p GT 0.1). In contrast, Stage III/IV disease (median: 2.34 ng/ml; n=43) exhibited highly significant TGF-beta(1) elevation (p LT 0.001) relative to HD. Further analysis revealed that TGF-beta(1) increase was predominantly attributed to Stage IV, metastatic disease patients (Q3=4.23 ng/ml) rather than to the group Stage III/IV (Q3=3.58 ng/ml). Using the plasma TGF-beta(1) concentration of 3.00 ng/ml as the cut-off value, two subgroups of patients were formed. Overall 2-year survival of the first subgroup, having elevated plasma TGF-beta(1) ( GT 3.00 ng/ml; n=10), was 10%. This was significantly decreased (p LT 0.05) compared to 52% survival observed for the second subgroup of patients with plasma TGF beta(1) values close to HD ( LT 3.00 ng/ml, n=19). Conclusion: We have performed a pilot study to determine the relationship between overall survival and TGF-beta(1) concentration in the blood of metastatic breast cancer patients. The survival was significantly reduced in the patients with elevated plasma TGF-beta(1) levels compared to that of the patients with plasma TGF-beta(1) levels close to normal. We propose that plasma TGF-beta(1) concentration may be a new tumour marker attributed to the presence of metastatic BC cells that may be used in selection of metastatic BC patients with poor prognosis. (c) 2006 Elsevier B.V. All rights reserved